{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:13:21Z","timestamp":1794014001917,"version":"4.8.0"},"reference-count":62,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2017.00891","type":"journal-article","created":{"date-parts":[[2017,7,28]],"date-time":"2017-07-28T03:41:21Z","timestamp":1501213281000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":71,"title":["Anti-Adhesion Therapies in Inflammatory Bowel Disease\u2014Molecular and Clinical Aspects"],"prefix":"10.3389","volume":"8","author":[{"given":"Sebastian","family":"Zundler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Weidinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Siegmund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,7,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.crohns.2014.03.005","article-title":"IBD and health-related quality of life\u2014discovering the true impact","volume":"8","author":"L\u00f6nnfors","year":"2014","journal-title":"J Crohns Colitis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nature11582","article-title":"Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease","volume":"491","author":"Jostins","year":"2012","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1002\/eji.200939601","article-title":"Clinical aspects of inflammatory bowel disease","volume":"39","author":"Siegmund","year":"2009","journal-title":"Eur J Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nri3661","article-title":"Cytokines in inflammatory bowel disease","volume":"14","author":"Neurath","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s11894-008-0104-x","article-title":"Recent advances in IBD pathogenesis: genetics and immunobiology","volume":"10","author":"Shih","year":"2008","journal-title":"Curr Gastroenterol Rep"},{"key":"B6","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1042\/CS20100027","article-title":"T-cell-directed therapies in inflammatory bowel diseases","volume":"118","author":"Monteleone","year":"2010","journal-title":"Clin Sci (Lond)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2174\/138945008784221198","article-title":"Mucosal T cell proliferation and apoptosis in inflammatory bowel disease","volume":"9","author":"Sturm","year":"2008","journal-title":"Curr Drug Targets"},{"key":"B8","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/nri2156","article-title":"Getting to the site of inflammation: the leukocyte adhesion cascade updated","volume":"7","author":"Ley","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nature01726","article-title":"Selective imprinting of gut-homing T cells by Peyer\u2019s patch dendritic cells","volume":"424","author":"Mora","year":"2003","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.immuni.2004.08.011","article-title":"Retinoic acid imprints gut-homing specificity on T cells","volume":"21","author":"Iwata","year":"2004","journal-title":"Immunity"},{"key":"B11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/ibd.20280","article-title":"Homing imprinting and immunomodulation in the gut: role of dendritic cells and retinoids","volume":"14","author":"Mora","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1056\/NEJM200010053431407","article-title":"T-cell function and migration\u2014two sides of the same coin","volume":"343","author":"von Andrian","year":"2000","journal-title":"N Engl J Med"},{"key":"B13","first-page":"97","article-title":"Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue","volume":"151","author":"Briskin","year":"1997","journal-title":"Am J Pathol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/0092-8674(93)90305-A","article-title":"Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1","volume":"74","author":"Berlin","year":"1993","journal-title":"Cell"},{"key":"B15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3389\/fimmu.2012.00127","article-title":"Chemokines and the signaling modules regulating integrin affinity","volume":"3","author":"Montresor","year":"2012","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1146\/annurev.immunol.25.022106.141618","article-title":"Structural basis of integrin regulation and signaling","volume":"25","author":"Luo","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/MIB.0000000000001029","article-title":"The \u03b14\u03b21 homing pathway is essential for ileal homing of Crohn\u2019s disease effector T cells in vivo","volume":"23","author":"Zundler","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/ni755","article-title":"JAM-1 is a ligand of the \u03b22 integrin LFA-1 involved in transendothelial migration of leukocytes","volume":"3","author":"Ostermann","year":"2002","journal-title":"Nat Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/ni1240","article-title":"Chemokine receptor CCR7 guides T cell exit from peripheral tissues and entry into afferent lymphatics","volume":"6","author":"Bromley","year":"2005","journal-title":"Nat Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1126\/science.1070238","article-title":"Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists","volume":"296","author":"Mandala","year":"2002","journal-title":"Science"},{"key":"B21","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1097\/MIB.0000000000001067","article-title":"Novel insights into the mechanisms of gut homing and antiadhesion therapies in inflammatory bowel diseases","volume":"23","author":"Zundler","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"B22","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.4049\/jimmunol.150.8.3459","article-title":"Integrin alpha E beta 7 mediates adhesion of T lymphocytes to epithelial cells","volume":"150","author":"Cepek","year":"1993","journal-title":"J Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"836","DOI":"10.2174\/156652409789105525","article-title":"Role of \u03b27 integrins in intestinal lymphocyte homing and retention","volume":"9","author":"Gorfu","year":"2009","journal-title":"Curr Mol Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/apt.12639","article-title":"Review article: anti-adhesion therapies for inflammatory bowel disease","volume":"39","author":"Lobat\u00f3n","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1056\/NEJMoa043335","article-title":"Natalizumab induction and maintenance therapy for Crohn\u2019s disease","volume":"353","author":"Sandborn","year":"2005","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1172\/JCI116575","article-title":"Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody","volume":"92","author":"Podolsky","year":"1993","journal-title":"J Clin Invest"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1053\/gast.1996.v111.pm8898653","article-title":"Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7","volume":"111","author":"Hesterberg","year":"1996","journal-title":"Gastroenterology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1056\/NEJMoa051586","article-title":"Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn\u2019s disease","volume":"353","author":"Van Assche","year":"2005","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1159\/000233284","article-title":"Targeted therapies in inflammatory bowel disease","volume":"27","author":"Siegmund","year":"2009","journal-title":"Dig Dis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1016\/j.cgh.2016.02.016","article-title":"Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease","volume":"14","author":"Amiot","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/apt.13594","article-title":"Vedolizumab induction therapy for inflammatory bowel disease in clinical practice \u2013 a nationwide consecutive German cohort study","volume":"43","author":"Baumgart","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"B34","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(14)60661-9","article-title":"Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial","volume":"384","author":"Vermeire","year":"2014","journal-title":"Lancet"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312439","article-title":"Blockade of \u03b1E\u03b27 integrin suppresses accumulation of CD8+ and Th9 lymphocytes from patients with IBD in the inflamed gut in vivo","author":"Zundler","year":"2016","journal-title":"Gut"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1172\/JCI44675","article-title":"CD8+ T cells with an intraepithelial phenotype upregulate cytotoxic function upon influenza infection in human lung","volume":"121","author":"Piet","year":"2011","journal-title":"J Clin Invest"},{"key":"B37","doi-asserted-by":"publisher","first-page":"845","DOI":"10.4049\/jimmunol.179.2.845","article-title":"Brain microenvironment promotes the final functional maturation of tumor-specific effector CD8+ T cells","volume":"179","author":"Masson","year":"2007","journal-title":"J Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1084\/jem.20040662","article-title":"Essential role for CD103 in the T cell-mediated regulation of experimental colitis","volume":"202","author":"Annacker","year":"2005","journal-title":"J Exp Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1084\/jem.20070590","article-title":"A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-\u03b2- and retinoic acid-dependent mechanism","volume":"204","author":"Coombes","year":"2007","journal-title":"J Exp Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1002\/eji.200939957","article-title":"Intestinal inflammation abrogates the tolerogenic properties of MLN CD103+ dendritic cells","volume":"40","author":"Laffont","year":"2010","journal-title":"Eur J Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1124\/jpet.109.153973","article-title":"The binding specificity and selective antagonism of vedolizumab, an anti-\u03b14\u03b27 integrin therapeutic antibody in development for inflammatory bowel diseases","volume":"330","author":"Soler","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"B42","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1093\/ecco-jcc\/jju027.021","article-title":"OP021. TURANDOT: a randomized, multicenter double-blind, placebo-controlled study of the safety and efficacy of anti-MAdCAM antibody PF-00547659 (PF) in patients with moderate to severe ulcerative colitis (UC)","volume":"9","author":"Vermeire","year":"2015","journal-title":"J Crohns Colitis"},{"key":"B43","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1093\/ecco-jcc\/jju027.022","article-title":"OP022. Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn\u2019s disease: results of the OPERA study","volume":"9","author":"D\u2019Haens","year":"2015","journal-title":"J Crohns Colitis"},{"key":"B44","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1093\/ecco-jcc\/jjw189","article-title":"\u03b1E\u03b27 integrin identifies subsets of pro-inflammatory colonic CD4+ T lymphocytes in ulcerative colitis","volume":"11","author":"Lamb","year":"2016","journal-title":"J Crohns Colitis"},{"key":"B45","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/ni.2920","article-title":"TH9 cells that express the transcription factor PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cells","volume":"15","author":"Gerlach","year":"2014","journal-title":"Nat Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1053\/gast.2001.26260","article-title":"A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn\u2019s disease","volume":"121","author":"Gordon","year":"2001","journal-title":"Gastroenterology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa020732","article-title":"Natalizumab for active Crohn\u2019s disease","volume":"348","author":"Ghosh","year":"2003","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1053\/j.gastro.2007.03.024","article-title":"Natalizumab for the treatment of active Crohn\u2019s disease: results of the ENCORE Trial","volume":"132","author":"Targan","year":"2007","journal-title":"Gastroenterology"},{"key":"B49","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/ecco-jcc\/jjw177","article-title":"Long-term efficacy of vedolizumab for ulcerative colitis","volume":"11","author":"Loftus","year":"2017","journal-title":"J Crohns Colitis"},{"key":"B50","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/ecco-jcc\/jjw176","article-title":"Long-term efficacy of vedolizumab for Crohn\u2019s disease","volume":"11","author":"Vermeire","year":"2017","journal-title":"J Crohns Colitis"},{"key":"B51","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/ecco-jcc\/jjw147","article-title":"Postoperative outcomes in vedolizumab-treated patients undergoing abdominal operations for inflammatory bowel disease","volume":"11","author":"Lightner","year":"2017","journal-title":"J Crohns Colitis"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/ajg.2016.236","article-title":"The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn\u2019s disease: results from the US VICTORY consortium","volume":"111","author":"Dulai","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1097\/MIB.0000000000001039","article-title":"Efficacy and safety of vedolizumab for induction of remission in inflammatory bowel disease \u2013 the Israeli real-world experience","volume":"23","author":"Kopylov","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/apt.13813","article-title":"Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease \u2013 a prospective multicenter observational study","volume":"44","author":"Stallmach","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease. Crohn\u2019s Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1053\/j.gastro.2015.10.041","article-title":"Association between response to etrolizumab and expression of integrin \u03b1E and granzyme A in colon biopsies of patients with ulcerative colitis","volume":"150","author":"Tew","year":"2016","journal-title":"Gastroenterology"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1136\/gut.2010.226548","article-title":"The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study","volume":"60","author":"Vermeire","year":"2011","journal-title":"Gut"},{"key":"B58","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0140-6736(17)30930-3","article-title":"Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"390","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"B59","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"B60","doi-asserted-by":"publisher","first-page":"S","DOI":"10.1016\/S0016-5085(15)32933-4","article-title":"Tu1346 skin and joint side effects in a subpopulation of anti-TNF experienced IBD patients, who respond to a treatment with vedolizumab, a humanized A4b7 integrin antibody","volume":"148","author":"Drvarov","year":"2015","journal-title":"Gastroenterology"},{"key":"B61","doi-asserted-by":"publisher","first-page":"S394","DOI":"10.1093\/ecco-jcc\/jjx002.741","article-title":"P617 Extraintestinal autoimmune phenomena during treatment with vedolizumab","volume":"11","author":"Lissner","year":"2017","journal-title":"J Crohns Colitis"},{"key":"B62","doi-asserted-by":"publisher","first-page":"764","DOI":"10.3389\/fimmu.2017.00764","article-title":"Clinical response to vedolizumab in UC patients is associated with changes in integrin expression profiles","volume":"8","author":"Fuchs","year":"2017","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.00891\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T18:55:28Z","timestamp":1692903328000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.00891\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,28]]},"references-count":62,"alternative-id":["10.3389\/fimmu.2017.00891"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2017.00891","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,28]]},"article-number":"891"}}